Jump to content

Drilldown: Medicines

Choose a table:


Medicines > classes : Classic Psychedelic or PDE5 Inhibitor or dissociative

Use the filters below to narrow your results.

generic:
brand:
None (86) · Cialis, Adcirca (1) · Delysid (historical, Sandoz, withdrawn 1965) (1) · DXM (1) · DXO (1) · Levitra, Staxyn (1) · Spravato (1) · Stendra (1) · Viagra, Revatio (1)
classes: (Click arrow to add another value)
mechanism:
5-HT2A agonist (26) · Potent 5-HT2A agonist (5) · LSD analogue; 5-HT2A agonist (4) · Prodrug of LSD; 5-HT2A agonist (4) · NMDA antagonist (3) · Contains LSA (2) · Contains mescaline (2) · NMDA antagonist; sigma receptor agonist (2)
uses:
None (89) · Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1) · '"`UNIQ--vote-00000040-QINU`"' (1) · '"`UNIQ--vote-00000669-QINU`"' (1) · '"`UNIQ--vote-00000705-QINU`"', '"`UNIQ--vote-00000706-QINU`"' (1) · '"`UNIQ--vote-00000738-QINU`"', '"`UNIQ--vote-00000739-QINU`"', '"`UNIQ--vote-0000073A-QINU`"' (1)
starting dose:
None (89) · 10 mg PRN; 2.5–5 mg daily for continuous coverage / BPH (1) · 10 mg ~1 h before sexual activity (1) · 100 mg ~15 min before sexual activity (1) · 50 mg ~1 h before sexual activity (ED); 20 mg TID (PAH) (1) · Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1)
preparations:
None (89) · 2.5, 5, 10, 20 mg tabs (1) · 2.5, 5, 10, 20 mg tabs (Levitra); 10 mg ODT (Staxyn) (1) · 25, 50, 100 mg tabs (Viagra); 20 mg tabs and 10 mg/mL oral suspension (Revatio) (1) · 28 mg/device (each dose uses 2 devices) (1) · 50, 100, 200 mg tabs (1)
fda max:
None (89) · 100 mg/d (ED); 20 mg TID (PAH) (1) · 20 mg/d (1) · 20 mg/d (ED, PRN); 5 mg/d (daily / BPH); 40 mg/d (PAH) (1) · 200 mg/d (100 mg/d if on CYP3A4 inhibitors) (1) · 84 mg per session (1)
routes:
None (88) · Intranasal (under direct medical supervision) (1) · IV (Revatio) (1) · Oral (5)
onset:
None (88) · 30 min (1) · 30–60 min (1) · 30–60 minutes (1) · Within hours of first administration (1) · ~15 min (fastest of the PDE5 inhibitors) (1) · ~30 min (1)
duration:
None (88) · 4–5 h (1) · 4–6 h (1) · 8–12 hours (1) · Acute effect ~24 hours; cumulative effect builds with repeated dosing (1) · Up to 36 h ("the weekend pill") (1) · ~4 h (1)
halflife:
None (88) · 3–5 hours (1) · 4–5 h (1) · ~17.5 h (1) · ~4 h (1) · ~5 h (1) · ~7-12 hours (1)
bioavailability:
None (88) · 70–90% (oral) (1) · Rapid absorption; absolute bioavailability not formally established (1) · Reasonable (not formally established as a percentage) (1) · ~15% (extensive hepatic first-pass) (1) · ~40% (1) · ~48% intranasal (1)
pregnancy:
None (88) · Avoid; may cause fetal harm (1) · Category B (3) · Category C (not relevant; not used in women) (1) · Not established (1)
legal:
None (88) · Rx, Schedule III (US). REMS program required. (1) · Rx-only in US (4) · Schedule I (United States) (1)

Showing below up to 94 results in range #1 to #94.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"